Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Comparing the Treatment of Clinically Significant Diabetic Macular Edema (CSDME) With 0.5mg Ranibizumab, 1.0mg Ranibizumab and 2.0mg Ranibizumab

NCT00440609 is registered in ClinicalTrials.gov with Philip J. ferrone, M.D. as lead sponsor.

NCT NCT00440609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00440609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Comparing the Treatment of Clinically Significant Diabetic Macular Edema (CSDME) With 0.5mg Ranibizumab, 1.0mg Ranibizumab and 2.0mg Ranibizumab
Lead sponsor
Philip J. ferrone, M.D.
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2007
Completion date
December 31, 2012
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clinically significant diabetic macular edema